Petrelintide vs Eloralintide
Petrelintide (ZP8396), from Zealand Pharma and Roche, and Eloralintide (LY3841136), from Lilly, are the two newest once-weekly amylin compounds in obesity research. Both reported Phase 2 results in the last year. This page compares them as research compounds.
UK single vials · Paused
Join the Eloralintide waitlist
Back in UK stock in about four to five weeks, all going well. Join the waitlist and we will email you when it lands.
Eloralintide 10mg is booked in for a full-panel independent test at Vanguard Laboratory: purity, quantity, endotoxins and sterility. Results from late October, in the COA Library.
| Petrelintide | Eloralintide | |
|---|---|---|
| Developer | Zealand Pharma with Roche | Eli Lilly |
| Development code | ZP8396 | LY3841136 |
| Molecule | Long-acting amylin analogue | Selective amylin receptor agonist |
| Administration in trials | Once weekly subcutaneous | Once weekly subcutaneous |
| Phase 2 result | Up to 10.7% at 42 weeks (placebo 1.7%) | 9.5% to 20.1% at 48 weeks (placebo 0.4%) |
| Stopped for side effects | 4.8% (placebo 4.9%) | More GI effects at higher doses |
| Next readout | ZUPREME-2 (type 2 diabetes), second half of 2026 | ENLIGHTEN Phase 3 under way |
| Peptx availability | Not stocked, waitlist on its profile | Waitlist, UK single vials |
- Developer
- Zealand Pharma with RocheEli Lilly
- Development code
- ZP8396LY3841136
- Molecule
- Long-acting amylin analogueSelective amylin receptor agonist
- Administration in trials
- Once weekly subcutaneousOnce weekly subcutaneous
- Phase 2 result
- Up to 10.7% at 42 weeks (placebo 1.7%)9.5% to 20.1% at 48 weeks (placebo 0.4%)
- Stopped for side effects
- 4.8% (placebo 4.9%)More GI effects at higher doses
- Next readout
- ZUPREME-2 (type 2 diabetes), second half of 2026ENLIGHTEN Phase 3 under way
- Peptx availability
- Not stocked, waitlist on its profileWaitlist, UK single vials
Same hormone, different design goals
Both compounds mimic amylin, the hormone released with insulin that acts in the hindbrain on satiety and meal size. Native amylin clumps into fibrils, so every analogue in this class is engineered for stability and a once-weekly half-life.
Zealand describes petrelintide as a long-acting amylin analogue built for high chemical and physical stability at neutral pH. Lilly describes eloralintide as a selective amylin receptor agonist. Petrelintide's results lead on tolerability; eloralintide's lead on the size of the weight reduction.
What the Phase 2 trials show
Roche reported in March 2026 that petrelintide reached up to 10.7% mean weight reduction at 42 weeks in the ZUPREME-1 trial, against 1.7% with placebo. Discontinuations for side effects were 4.8%, against 4.9% on placebo, and the most effective arm had no vomiting.
Lilly's eloralintide Phase 2, published in The Lancet in November 2025, reached 9.5% to 20.1% at 48 weeks across its dose arms, against 0.4% with placebo. The trials differ in length, population and dosing, so the figures are not a head-to-head comparison.
Where each programme goes next
Petrelintide's second Phase 2 trial, ZUPREME-2 in people with type 2 diabetes, is due to report in the second half of 2026, and Roche plans a Phase 2 study combining it with its incretin candidate CT-388. Eloralintide is in Lilly's ENLIGHTEN Phase 3 programme, and its combination with tirzepatide reported a 48-week Phase 2b in September 2026.
Bottom line for research labs
Petrelintide and Eloralintide are the two amylin compounds to watch. Eloralintide has the larger published Phase 2 effect and is already in Phase 3; Petrelintide has the cleaner tolerability story and more readouts due in 2026. For amylin receptor research today, Eloralintide is the better documented of the two.